This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.

Inclusion Criteria:

• Patients must have completed the Week 26 visit of TVP 1012/133 (Visit 06) in accordance with the protocol.
• Women must be postmenopausal, surgically sterile, or using adequate birth control methods. Women of childbearing potential must have a negative pregnancy test at Baseline/Month 0.
• Patients must be willing and able to give informed consent.

Exclusion Criteria:

• Serious or severe, test drug-related (probable or definite) adverse reaction in study TVP 1012/133.
• Premature discontinuation from study TVP 1012/133 for any reason.
• A clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary, hepatic, renal, or metabolic diseases; or malignancies, as determined by medical history, physical exam, skin evaluation, laboratory tests, chest x-ray, or electrocardiogram (ECG).